We are live on ! Find out more
OTLK icon

Outlook Therapeutics

56 hedge funds and large institutions have $89.9M invested in Outlook Therapeutics in 2024 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

652% more capital invested

Capital invested by funds: $12M → $89.9M (+$78M)

57.47% more ownership

Funds ownership: 0.58%58.05% (+57%)

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

36% less funds holding

Funds holding: 8756 (-31)

66% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 47

Holders
56
Holders Change
-31
Holders Change %
-35.63%
% of All Funds
0.81%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
16
Increased
17
Reduced
17
Closed
47
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
IAMOG
101
Investors Asset Management of Georgia
Georgia
-$3.94K -500 Closed
PNC Financial Services Group
102
PNC Financial Services Group
Pennsylvania
-$160 -20 Closed

OTLK Hedge Fund Activity: Q1 2024 in Review

56 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2024, worth a combined $89.9M — up 652% from $12M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of OTLK and 16 opened new positions — a net loss of 31 holders — while 17 trimmed existing stakes and 17 added.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $13.1M. The largest seller was Morgan Stanley, cutting an estimated $311K.

  • 56 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2024, down from 87 in Q4 2023.
  • Funds reported $89.9M of Outlook Therapeutics stock for Q1 2024, up 652% quarter-over-quarter.
  • 16 funds opened new Outlook Therapeutics positions in Q1 2024 and 47 closed out, a net change of -31 holders.
  • The largest Outlook Therapeutics buyer in Q1 2024 was Tang Capital Management, an estimated $13.1M added.
  • The largest Outlook Therapeutics seller in Q1 2024 was Morgan Stanley, an estimated $311K sold.

Based on aggregated 13F filings for Q1 2024.